Company Filing History:
1 out of 216 
1 out of 1 
1 out of 11 Years Active: 2001-2004
Title: John R Hurst: Innovator in Chemical Analysis and Molecular Screening
Introduction
John R Hurst is a notable inventor based in San Diego, CA. He has made significant contributions to the fields of chemical analysis and molecular screening, holding a total of 3 patents. His work focuses on developing systems and methods that enhance the understanding and organization of chemical entities.
Latest Patents
One of Hurst's latest patents is titled "System and method for database similarity join." This patent discloses systems and methods for organizing information by inferring characteristics regarding entities from similar entities. This innovative approach, referred to as a "fuzzy similarity join," is particularly exemplified through a chemical similarity join. The disclosed systems and methods are especially useful for chemical compound analysis in pharmaceutical development. Another significant patent is "Methods for identifying a molecule that may bind to a target molecule." This patent outlines methods that can be implemented in computer systems to screen a database of candidate molecules. These methods determine the force field of a target molecule only once, allowing for the screening of a large number of candidate molecules efficiently.
Career Highlights
Throughout his career, John R Hurst has worked with prominent companies in the pharmaceutical and chemical industries. Notable among these are Arena Pharmaceuticals, Inc. and Chemnavigator, Inc. His experience in these organizations has contributed to his expertise in the field.
Collaborations
Hurst has collaborated with several professionals in his field, including Scott G Hutton and Trevor William Heritage. These collaborations have likely enriched his work and contributed to his innovative patents.
Conclusion
John R Hurst is a distinguished inventor whose work in chemical analysis and molecular screening has made a significant impact. His patents reflect his commitment to advancing the field and improving methodologies in pharmaceutical development.